Yarkadas Hayati 4
4 · Xylem Inc. · Filed Mar 3, 2026
Research Summary
AI-generated summary of this filing
Xylem (XYL) EVP Yarkadas Hayati Receives Stock Awards & Options ~$2.64M
What Happened
Yarkadas Hayati, EVP & President of Xylem, received multiple stock award vestings and new equity grants on March 1–2, 2026. Vested performance-based stock units delivered 4,456 (TSR), 3,679 (Adjusted EBITDA), 2,501 (Revenue) and 1,761 (ESG) shares at $128.98 each (totaling $1,599,0**;**65). An additional 2,274 shares were recorded at $0.00 (dividend reinvestment). Hayati was also granted derivative equity (8,102 shares value recorded at $128.98 = $1,044,996) representing non‑qualified stock options scheduled to vest in thirds in 2027–2029. To cover tax withholding, 565, 94 and 117 shares were withheld (disposed) for a total withholding of 776 shares ($100,089). Net change: +22,773 shares acquired − 776 withheld = +21,997 net shares.
Key Details
- Transaction dates: March 1–2, 2026. Filing date: March 3, 2026 (Form 4 accession 0001524472-26-000033). Filing appears timely.
- Prices and values recorded: vested shares at $128.98 each; total gross value of acquisitions shown ≈ $2,643,961 (does not assign value to $0 dividend-reinvested shares).
- Tax withholding (dispositions): 776 shares withheld, proceeds ≈ $100,089. These were labeled as tax-withholding disposals (code F).
- Notable footnotes: F1–F5 describe vesting of performance-based units (TSR, Adj. EBITDA, Revenue, ESG); F2 = dividend reinvestment; F6 = restricted stock units scheduled to vest in thirds; F10 = non‑qualified stock options scheduled to vest in thirds. F7–F9 explain the specific withholdings to satisfy tax liabilities.
- Shares owned after transaction: not reported in the supplied filing details.
Context
- Most of these transactions are award vestings and planned grants (code A) and routine tax-withholding (code F), not open‑market purchases or sales. Vestings and grant of options/RSUs are common executive compensation events and do not necessarily indicate a near-term buy/sell decision.
- The 8,102-share derivative entry reflects option grants (or similar) that vest over future years (one‑third increments in 2027–2029), not immediate exercised-and-sold shares.
- For retail investors: award vestings increase insider ownership but are a standard compensation mechanism; tax‑withholding dispositions are routine and reduce the net new shares received.
Insider Transaction Report
Form 4
Xylem Inc.XYL
Yarkadas Hayati
EVP & President, WI
Transactions
- Award
Common Stock
[F1][F2]2026-03-01$128.98/sh+4,456$574,735→ 24,142 total - Award
Common Stock
[F3]2026-03-01$128.98/sh+3,679$474,517→ 27,821 total - Award
Common Stock
[F4]2026-03-01$128.98/sh+2,501$322,579→ 30,322 total - Award
Common Stock
[F5]2026-03-01$128.98/sh+1,761$227,134→ 32,083 total - Award
Common Stock
[F6]2026-03-02+2,274→ 34,357 total - Tax Payment
Common Stock
[F7]2026-03-02$128.98/sh−565$72,874→ 33,792 total - Tax Payment
Common Stock
[F8]2026-03-02$128.98/sh−94$12,124→ 33,698 total - Tax Payment
Common Stock
[F9]2026-03-02$128.98/sh−117$15,091→ 33,581 total - Award
Non-Qualified Stock Option (Right to Buy)
[F10]2026-03-02$128.98/sh+8,102$1,044,996→ 8,102 totalExercise: $128.98Exp: 2036-03-02→ Common Stock (8,102 underlying)
Footnotes (10)
- [F1]Reflects the acquisition of 4,456 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Total Shareholder Return.
- [F10]Reflects an award of non-qualified stock options pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one-third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
- [F2]Includes additional shares due to dividend reinvestment.
- [F3]Reflects the acquisition of 3,679 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Adjusted EBITDA.
- [F4]Reflects the acquisition of 2,501 shares of common stock upon vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to Revenue.
- [F5]Reflects the acquisition of 1,761 shares of common stock upon vesting of performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016), upon achievement of performance criteria related to ESG performance.
- [F6]Reflects an award of restricted stock units pursuant to the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016) that are scheduled to vest in one third increments on March 1, 2027, March 1, 2028 and March 1, 2029.
- [F7]Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of performance-based stock units granted on March 1, 2023 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24 2016).
- [F8]Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of ESG performance-based stock units granted on March 1, 2021 under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February, 24, 2016).
- [F9]Reflects the withholding of shares of common stock to pay the tax liability incident to the vesting of restricted stock units granted on March 1, 2023 (75) and March 1, 2024 (42) under the Xylem 2011 Omnibus Incentive Plan (Amended and Restated February 24, 2016).
Signature
/s/ Mike Nazario, by power of attorney for Hayati Yarkadas|2026-03-03